Key result
Transoesophageal echocardiography-related adverse events occurred in 5.3% of patients undergoing structural heart disease interventions, with lower haemoglobin and OSAS identified as risk factors.
Why the study?
The incidence of transoesophageal echocardiography-related adverse events during structural heart disease interventions under procedural sedation and their potential risk factors were to be determined.
What is the incidence and what are the risk factors for transoesophageal echocardiography-related adverse events during structural heart disease interventions under procedural sedation?
Observational (n=898)
No
What is the incidence and what are the risk factors for transoesophageal echocardiography-related adverse events during structural heart disease interventions under procedural sedation?
Transoesophageal echocardiography during structural heart disease interventions under procedural sedation carries a 5.3% risk of adverse events, particularly pneumonia and bleeding, with higher risk in percutaneous mitral valve repair, lower baseline hemoglobin, and obstructive sleep apnea.
No takes yet. Share an insight, caveat, or question.
May warrant pre-procedural risk stratification in PMVR and patients with anemia or OSA; hypothesis-generating for mitigation trials in structural interventions.
Afzal et al. (2021) conducted an observational in Structural heart disease (n=898). Transoesophageal echocardiography (TOE) was evaluated on TOE-related adverse events (AEs). Transoesophageal echocardiography-related adverse events occurred in 5.3% of patients undergoing structural heart disease interventions, with lower haemoglobin and OSAS identified as risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: